Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Andreas Schneeweiß et al.|Annals of Oncology|2021Cited by 724
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugsNiklas Gremke, Thorsten Stiewe, Isabelle Besong et al.|Signal Transduction and Targeted Therapy|2025Cited by 19